Skip to main content
Past Event

Friends of Cancer Research-Brookings Conference on Clinical Cancer Research

To address critical issues in the development of new oncology drugs, Friends of Cancer Research and the Engelberg Center for Health Care Reform will co-host the seventh annual Conference on Clinical Cancer Research. This annual conference brings together leaders in cancer drug development from federal health and regulatory agencies, academic research, and the private sector for focused discussions on key issues surrounding the development and regulation of cancer drugs and therapies. This year’s conference will feature three panels that will propose unique approaches toward current challenges in drug development. 

Agenda

Panel One: Potential Strategies for Non-Randomized Evaluation of New Drugs

M

Mace Rothenberg

Senior Vice President, Clinical Development/Medical Affairs - Pfizer

R

Rich Simon

Chief, Biometric Research Branch - National Cancer Institute

R

Richard Pazdur

Director, Office of Oncology Products - U.S. Food and Drug Administration

Panel Two: Improving Evidence Developed From Population-Level Experience with Targeted Agents

S

Sam Nussbaum

Executive Vice President, Clinical Health Policy and Chief Medical Officer - WellPoint, Inc.

D

Dane Dickson

Director of Clinical Science - MoIDX, Palmetto GBA

R

Richard Pazdur

Director, Office of Oncology Products - U.S. Food and Drug Administration

Panel Three: Consideration of Summary Review of Supplemental NDA/BLA Submissions in Oncology

R

Rachel Sherman

Principal, Drug and Biological Drug Products - Greenleaf Health LLC

T

Tatiana Prowell

Breast Cancer Scientific Lead, Division of Oncology Products 1, Office of Hematology & Oncology Products - U.S. Food and Drug Administration

L

Laurie Strawn

Associate Director, Worldwide Regulatory Strategy - Pfizer

K

Kannan Natarajan

Senior Vice President and Global Head - Novartis Pharmaceuticals

R

Raji Sridhara

Acting Director, Division of Biometrics V - U.S. Food and Drug Administration

R

Robyn Lim

Senior Science Advisor - Health Canada

Morning Keynote: A Path to 21st Century Cures

H

Hon. Fred Upton

Chairman - United States House of Representatives, Energy & Commerce Committee

Lunch Keynote: State of FDA's Breakthrough Therapy Designation

J

Janet Woodcock

Director, Center for Drug Evaluation and Research - US Food and Drug Administration

Welcome

E

Ellen Sigal

Chairperson and Founder - Friends of Cancer Research

More Information

To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.

More

Get a weekly events calendar from Brookings